Patent ID: 6939855

Claim:
A method of treating an inflammatory disorder in a mammalian patient, which disorder involves binding of alpha-9 integrin to an alpha-9 integrin ligand in a mammalian patient, and which disorder is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, viral meningitis, encephalitis, and ulcerative colitis said method comprising administering to a mammalian subject in need thereof an effective dosage of an alpha-9 integrin antagonist compound which compound is represented by the formula: R 1 —SO 2 —NR 2 —CHR 3 —Q—CHR 5 —CO 2 H wherein: R 1 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl; R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and R 1 and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R 1 can form a heterocyclic or a substituted heterocyclic group; R 3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and, when R 2 does not form a heterocyclic group with R 1 , R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 can form a heterocyclic or a substituted heterocyclic group; R 5 is —(CH 2 ) x —Ar—R 5′ where R 5′ is selected from the group consisting of —O—Z—NR 8 R 8′ and —O—Z—R 12 wherein R 8 and R 8′ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, and where R 8 and R 8′ are joined to form a heterocyclic or substituted heterocycle, R 12 is selected from the group consisting of heterocycle and substituted heterocycle, and Z is selected from the group consisting of —C(O)— and —SO 2 —, Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, X is an integer of from 1 to 4; Q is —C(X)NR 7 — wherein R 7 is selected from the group consisting of hydrogen and alkyl; and X is selected from the group consisting of oxygen and sulfur; and pharmaceutically acceptable salts thereof, wherein said compound has a K i or IC 50 of less than 100 μM, as determined in an assay that measures inhibition of binding between alpha-9 integrin and alpha-9 integrin ligand.